ralinepag
ralinepag: developed by 2 companies · 3 clinical trials tracked.
ralinepag evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
What is verified about ralinepag, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| ARENA PHARMACEUTICALS INC (ARNA) | Phase 3 |
| UNITED THERAPEUTICS Corp (UTHR) PAH; Pulmonary Hypertension | Phase 3 |
Clinical Trials (3)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
Primary endpoint: Change From Baseline in Peak VO2 Assessed by CPET
A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepag in Subjects With World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH)
Primary endpoint: Number of subjects with treatment-emergent adverse events [Safety and Tolerability]
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Primary endpoint: Time from randomization to the first adjudicated protocol-defined clinical worsening event
Frequently asked questions
Who is developing ralinepag?
ralinepag is being developed by ARENA PHARMACEUTICALS INC, UNITED THERAPEUTICS Corp.
How many clinical trials involve ralinepag?
BioSniper tracks 3 clinical trials involving ralinepag.